SDZ 224-015
Modify Date: 2024-01-10 10:39:35
SDZ 224-015 structure
|
Common Name | SDZ 224-015 | ||
|---|---|---|---|---|
| CAS Number | 161511-45-1 | Molecular Weight | 652.52 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C30H35Cl2N3O9 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of SDZ 224-015SDZ 224-015 is an orally active inhibitor of the interleukin-1 beta (IL-1β) converting enzyme and caspase-1. SDZ 224-015 possesses anti-COVID-19 activity, targeting Mpro (IC50 of 30 nM)[1][2]. |
| Name | SDZ 224-015 |
|---|
| Description | SDZ 224-015 is an orally active inhibitor of the interleukin-1 beta (IL-1β) converting enzyme and caspase-1. SDZ 224-015 possesses anti-COVID-19 activity, targeting Mpro (IC50 of 30 nM)[1][2]. |
|---|---|
| Related Catalog | |
| In Vivo | SDZ 224-015 (0.3-300 μg/kg) potently reduces carrageenin-induced paw oedema[2]. SDZ 224-015 (0.2-5 mg/kg, p.o.) displays analgesic activity in the Randall-Selitto yeast-inflamed paw pressure test, significant at a dose of 1 mg/kg[2]. |
| References |
| Molecular Formula | C30H35Cl2N3O9 |
|---|---|
| Molecular Weight | 652.52 |